SSA
GILD icon

Schonfeld Strategic Advisors’s Gilead Sciences GILD Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,000
Closed -$999K – 2235
2025
Q3 		$999K Buy
+9,000
New +$1.02M 0.01% 1369
2024
Q2 		– Sell
-100,000
Closed -$7.33M – 2306
2024
Q1 		$7.33M Buy
+100,000
New +$7.69M 0.05% 491

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Schonfeld Strategic Advisors's GILD Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Gilead Sciences (GILD) in Q4 2025, closing a stake of 248,895 shares — an estimated $27.6M sold.

Schonfeld Strategic Advisors first reported a position in GILD in Q1 2016 and held it in 33 quarters. The position peaked at $53.4M in Q2 2024. 2,216 funds tracked by Wall St. Rank hold GILD as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Gilead Sciences position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 248,895 Gilead Sciences shares in Q4 2025, an estimated $27.6M.
  • Schonfeld Strategic Advisors first reported a position in Gilead Sciences in Q1 2016 and held it in 33 quarters.
  • Schonfeld Strategic Advisors's Gilead Sciences position peaked at $53.4M in Q2 2024.
  • 2,216 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.